Introduction to deltasone (prednisone)
Deltasone is a well-established brand name for prednisone, a synthetic corticosteroid medication that has been a foundation of anti-inflammatory and immunosuppressive therapy for over six decades. Prednisone is a prodrug that is converted by the liver into its active form, prednisolone, which then exerts potent glucocorticoid effects throughout the body. With approximately four to five times the anti-inflammatory potency of the naturally occurring hormone cortisol and moderate mineralocorticoid activity, prednisone has an important middle ground between weaker corticosteroids like hydrocortisone and more potent agents like dexamethasone. For patients requiring reliable access to this essential medication, a Happy Family Store provides a convenient and affordable option for obtaining Deltasone and other corticosteroid products.
Prednisone is one of the most commonly prescribed corticosteroids in clinical practice, owing to its well-characterized efficacy, predictable pharmacokinetics, and extensive track record of use across a vast range of medical conditions. The medication is available primarily in oral tablet form, with strengths ranging from 1 mg to 50 mg, though injectable prednisolone (the active form) is also available for parenteral administration. The flexibility in dosing allows clinicians to tailor therapy to the specific needs of each patient and condition.
The clinical utility of Deltasone spans virtually every medical specialty. It is used to treat inflammatory and autoimmune conditions such as rheumatoid arthritis, lupus, inflammatory bowel disease, and asthma; allergic conditions including severe allergic reactions and drug hypersensitivity; certain hematologic malignancies and blood disorders; and as immunosuppressive therapy for organ transplant recipients. The breadth of its applications reflects fundamental role that inflammation plays in human disease and the potency of corticosteroids in suppressing inflammatory responses.
Pharmacology and mechanism of action
Prednisone itself is pharmacologically inactive and functions as a prodrug that must be converted by the liver to its active metabolite, prednisolone. This conversion is mediated by the enzyme 11-beta-hydroxysteroid dehydrogenase type 1, which reduces the 11-keto group of prednisone to the 11-beta-hydroxy group of prednisolone. The conversion is efficient under normal conditions, though it may be impaired in patients with severe hepatic disease, which is why prednisolone is sometimes preferred over prednisone in patients with liver dysfunction.
Once activated, prednisolone diffuses across target cell membranes and binds to the glucocorticoid receptor located in the cytoplasm. This binding triggers a conformational change that releases the receptor from its associated heat shock proteins, allowing the activated receptor-ligand complex to translocate into the cell nucleus. Within the nucleus, the complex binds to glucocorticoid response elements (GREs) in the DNA, regulating the transcription of numerous genes involved in inflammation, immunity, and metabolism.
The anti-inflammatory effects of prednisolone are mediated primarily through transrepression, where the activated glucocorticoid receptor interacts with pro-inflammatory transcription factors such as NF-kappa-B and AP-1, preventing them from activating the expression of inflammatory genes. This reduces the production of pro-inflammatory cytokines (including interleukin-1, interleukin-6, and tumor necrosis factor-alpha), chemokines, adhesion molecules, and inflammatory enzymes such as cyclooxygenase-2 and inducible nitric oxide synthase.
Prednisolone also promotes transactivation, increasing the expression of anti-inflammatory proteins including lipocortin-1 (which inhibits phospholipase A2), interleukin-10, and I-kappa-B-alpha. The combined effect of decreased pro-inflammatory mediators and increased anti-inflammatory proteins results in potent and broad-spectrum suppression of inflammatory responses at the cellular and tissue levels.
The immunosuppressive effects of prednisone result from its ability to inhibit the proliferation and function of multiple immune cell types. It reduces the number of circulating T lymphocytes by inducing apoptosis and redistributing cells from the circulation to lymphoid tissues. It suppresses B lymphocyte function and antibody production, inhibits macrophage activation and antigen presentation, and decreases the survival and activity of eosinophils and mast cells. These effects are beneficial in autoimmune and allergic conditions and contribute to the increased risk of infection associated with corticosteroid therapy.
Medical uses and indications
Deltasone is approved for the treatment of an extensive list of medical conditions, making it one of the most versatile medications in clinical use. In rheumatologic diseases, prednisone provides rapid symptom relief for patients with rheumatoid arthritis, systemic lupus erythematosus, polymyalgia rheumatica, giant cell arteritis, psoriatic arthritis, ankylosing spondylitis, and various vasculitides. The medication reduces joint swelling, pain, and morning stiffness, improving physical function and quality of life. In giant cell arteritis and polymyalgia rheumatica, prednisone is the standard of care and often required for extended periods.
In dermatological conditions, prednisone is used to treat severe inflammatory skin diseases including pemphigus vulgaris, bullous pemphigoid, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, mycosis fungoides, and severe psoriasis. These conditions often require higher doses of corticosteroids for initial control, followed by gradual tapering as the disease responds.
Respiratory diseases treated with prednisone include severe asthma, chronic obstructive pulmonary disease (COPD) exacerbations, sarcoidosis, idiopathic pulmonary fibrosis, aspiration pneumonitis, and hypersensitivity pneumonitis. In asthma, short courses of oral prednisone are used for acute exacerbations to reduce airway inflammation and improve lung function. In sarcoidosis, prednisone is first-line therapy for patients with progressive pulmonary disease or significant extrapulmonary involvement.
Gastrointestinal conditions including ulcerative colitis, Crohn’s disease, and celiac disease may be treated with prednisone during acute flares. The medication reduces intestinal inflammation, controls diarrhea and abdominal pain, and promotes mucosal healing. However, due to side effects with long-term use, prednisone is typically reserved for induction of remission rather than maintenance therapy in inflammatory bowel disease, with steroid-sparing agents used for long-term disease control.
Hematologic conditions treated with prednisone include autoimmune hemolytic anemia, immune thrombocytopenic purpura (ITP), and pure red cell aplasia. In ITP, prednisone increases platelet counts by reducing the destruction of antibody-coated platelets by the spleen and by decreasing anti-platelet antibody production. In certain hematologic malignancies including multiple myeloma, lymphoma, and acute lymphoblastic leukemia, prednisone is used as a direct chemotherapeutic agent and an adjunct to reduce treatment-related inflammation and side effects.
Neurologic indications for prednisone include multiple sclerosis (particularly for acute relapses), myasthenia gravis, Duchenne muscular dystrophy, and certain neuropathies. In multiple sclerosis, high-dose corticosteroids accelerate recovery from acute neurologic deficits by reducing inflammation and demyelination within the central nervous system. In Duchenne muscular dystrophy, prednisone has been shown to improve muscle strength and function and to slow disease progression.
Ophthalmic conditions including uveitis, iritis, choroiditis, sympathetic ophthalmia, and certain types of conjunctivitis may be treated with systemic or topical prednisone. The anti-inflammatory effects help preserve vision by reducing swelling and preventing scar formation in the delicate tissues of the eye. Renal conditions such as nephrotic syndrome and certain glomerulonephritides also respond well to prednisone therapy.
Allergic conditions including severe seasonal or perennial allergic rhinitis refractory to other treatments, angioedema, serum sickness, drug hypersensitivity reactions, and severe urticaria can be effectively managed with short courses of prednisone. The medication suppresses both the immediate and delayed phases of allergic reactions, providing comprehensive symptom relief.
Organ transplant recipients typically receive prednisone as part of their immunosuppressive regimen, often in combination with calcineurin inhibitors (cyclosporine, tacrolimus) and antimetabolites (mycophenolate, azathioprine). The corticosteroid component helps prevent acute rejection and contributes to long-term graft survival, though efforts are made to minimize steroid exposure over time due to cumulative side effects.
Dosage forms and administration
Deltasone is available in oral tablet form in multiple strengths to accommodate the wide range of therapeutic requirements. Common tablet strengths include 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, and 50 mg. The 5 mg and 10 mg tablets are the most frequently prescribed strengths for maintenance therapy, while higher strengths are used for initial high-dose induction therapy in severe conditions.
Prednisone tablets are typically taken once daily in the morning, which mimics the natural diurnal rhythm of cortisol secretion and minimizes suppression of the hypothalamic-pituitary-adrenal (HPA) axis. For certain conditions, divided doses (two to four times daily) may be prescribed for more severe disease activity. The tablets should be swallowed whole with a full glass of water and can be taken with or without food, though taking them with food may reduce gastrointestinal irritation.
The dosing of prednisone is highly individualized and depends on multiple factors including the specific condition being treated, its severity, the patient’s age and weight, their response to therapy, and their tolerance of side effects. Dosing regimens are generally categorized as low-dose (less than 7.5 mg daily), moderate-dose (7.5 mg to 30 mg daily), high-dose (30 mg to 100 mg daily), and very high-dose or pulse therapy (greater than 100 mg daily, often administered intravenously as methylprednisolone).
For many inflammatory and autoimmune conditions, treatment is initiated at a relatively high dose to achieve rapid disease control, followed by gradual tapering to the lowest effective maintenance dose. The tapering process must be individualized and may take weeks to months, depending on the duration of previous therapy and the underlying disease. Abrupt discontinuation of prednisone after prolonged use can lead to acute adrenal insufficiency.
Alternate-day dosing is a strategy sometimes employed for patients requiring long-term corticosteroid therapy. By administering the total 48-hour dose as a single dose every other morning, this regimen reduces HPA axis suppression while maintaining therapeutic efficacy for many conditions. However, not all patients or diseases respond adequately to alternate-day dosing.
Pharmacokinetics
Following oral administration, prednisone is rapidly and completely absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 1 to 2 hours. The medication undergoes first-pass metabolism in the liver where it is converted to its active metabolite prednisolone. The conversion is efficient, with approximately 80% of an oral dose reaching the systemic circulation as prednisolone in patients with normal hepatic function.
Prednisolone is approximately 70% to 80% bound to plasma proteins, primarily corticosteroid-binding globulin and albumin. The unbound fraction is pharmacologically active and can diffuse into tissues to exert therapeutic effects. The volume of distribution of prednisolone is approximately 0.5 to 1 L/kg, indicating extensive distribution throughout the body.
The elimination half-life of prednisolone is approximately 2 to 4 hours, though its biologic half-life (duration of effect) is longer, ranging from 18 to 36 hours. This discrepancy between plasma half-life and biologic half-life is characteristic of corticosteroids and reflects time required for the transcriptional and translational changes induced by the medication to be reversed.
Prednisolone is metabolized primarily in the liver by CYP3A4 and other enzymes, and its metabolites are excreted in the urine. Approximately 20% to 30% of a dose is excreted unchanged in the bile and feces. Patients with severe hepatic impairment may have reduced conversion of prednisone to prednisolone and may benefit from treatment with prednisolone directly rather than prednisone.
Side effects and adverse reactions
The side effect profile of prednisone is extensive and includes effects on virtually every organ system. The nature and severity of side effects depend on the dose, duration of therapy, and individual patient factors. Short-term use (less than two to three weeks) is generally well-tolerated, while long-term use carries significant risks that require careful monitoring and preventive measures.
Endocrine and metabolic effects are among the most common. Hyperglycemia and worsening of diabetes mellitus occur frequently, and patients without pre-existing diabetes may develop steroid-induced hyperglycemia or, in some cases, steroid-induced diabetes. Increased appetite and weight gain are almost universal with prolonged use, and the characteristic fat redistribution of Cushing’s syndrome, including moon face, buffalo hump, and central obesity, develops over time.
Musculoskeletal effects include osteoporosis, which is one of the most significant long-term complications of prednisone therapy. Corticosteroids inhibit bone formation and promote bone resorption, leading to decreased bone mineral density and increased fracture risk. This effect is most pronounced in the first few months of therapy and is partially reversible upon discontinuation. Proximal myopathy affecting the thighs and shoulders also occurs, manifesting as difficulty rising from chairs or climbing stairs.
Gastrointestinal effects include an increased risk of peptic ulcer disease, though this risk appears to be lower with glucocorticoid monotherapy than when combined with NSAIDs. Pancreatitis, fatty liver, and esophageal reflux may also occur. The medication can mask the symptoms of gastrointestinal perforation, potentially delaying diagnosis of this surgical emergency.
Cardiovascular effects include hypertension, sodium and fluid retention, hypokalemia, and an increased risk of atherosclerosis and thromboembolic disease. These effects are mediated in part by the mineralocorticoid activity of prednisone, which is moderate compared to other corticosteroids.
Psychiatric effects are common and include mood swings, euphoria, irritability, insomnia, and anxiety. More severe effects including depression, mania, psychosis, and delirium can occur, particularly at higher doses. The risk of psychiatric effects may be higher in patients with pre-existing psychiatric disorders. These effects are generally reversible with dose reduction or discontinuation.
Dermatologic effects include skin thinning, easy bruising, striae, impaired wound healing, acne, and increased susceptibility to skin infections. Cataracts, particularly posterior subcapsular cataracts, and glaucoma are important ophthalmic complications of long-term prednisone therapy. Regular eye examinations are recommended for patients on prolonged treatment.
Immunosuppression increases susceptibility to infections and can reactivate latent infections including tuberculosis, hepatitis B, and herpes zoster. Patients should be screened for latent infections before initiating long-term corticosteroid therapy and monitored for signs of infection during treatment.
Drug interactions
Prednisone interacts with a substantial number of other medications. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, and indomethacin increase the risk of gastrointestinal ulceration and bleeding when combined with prednisone. This interaction is particularly concerning because both medications are commonly used in patients with rheumatologic conditions.
Anticoagulants such as warfarin can have unpredictable interactions with prednisone, with some patients experiencing increased anticoagulant effect and others experiencing decreased effect. More frequent monitoring of the INR is recommended when prednisone therapy is initiated, adjusted, or discontinued in patients receiving warfarin.
Antidiabetic medications typically require dose adjustment when prednisone is initiated, as the hyperglycemic effects of the corticosteroid can increase insulin and oral hypoglycemic requirements. Blood glucose levels should be monitored closely during treatment.
Medications that induce CYP3A4, including rifampin, phenytoin, carbamazepine, and phenobarbital, can accelerate the metabolism of prednisolone and reduce its effectiveness, potentially requiring higher doses of prednisone. Conversely, CYP3A4 inhibitors such as ketoconazole, itraconazole, and certain protease inhibitors can increase prednisolone levels and the risk of side effects.
Contraindications and precautions
Systemic fungal infections and known hypersensitivity to prednisone or any component of the formulation are contraindications to therapy. Live vaccines should not be administered during immunosuppressive therapy. Caution is required in patients with congestive heart failure, hypertension, renal impairment, diabetes, osteoporosis, glaucoma, cataracts, seizure disorders, and active or latent infections.
Clinical applications in renal disease
Prednisone plays a critical role for several renal conditions, particularly nephrotic syndrome and various forms of glomerulonephritis. In minimal change disease, which is the most common cause of nephrotic syndrome in children, prednisone is the standard first-line therapy. High-dose prednisone at 1 mg to 2 mg per kilogram daily induces remission in approximately 80% to 90% of children within 4 to 8 weeks. Adults with minimal change disease also respond well, though the response rate is somewhat lower and the time to response may be longer.
Focal segmental glomerulosclerosis (FSGS) is a more challenging form of nephrotic syndrome with a more variable response to corticosteroid therapy. Patients with primary FSGS who respond to prednisone have a better prognosis than non-responders, but many patients require additional immunosuppressive agents such as calcineurin inhibitors or cyclophosphamide to achieve remission. The optimal duration of prednisone therapy in FSGS remains controversial, with some protocols recommending prolonged courses of 4 to 6 months.
Membranous nephropathy, another cause of nephrotic syndrome in adults, may be treated with prednisone in combination with alkylating agents or calcineurin inhibitors, though corticosteroid monotherapy has not been shown to be effective for this condition. The use of prednisone in lupus nephritis is essential, typically in combination with cyclophosphamide or mycophenolate for proliferative forms of the disease. The prednisone dose is tapered as the renal disease responds, with most patients requiring low-dose maintenance therapy for extended periods.
Clinical applications in respiratory medicine
In asthma management, prednisone is used primarily for acute exacerbations rather than chronic maintenance therapy. Short courses of oral prednisone, typically 0.5 mg to 1 mg per kilogram daily for 5 to 10 days, reduce airway inflammation, improve lung function, and decrease the risk of relapse following an acute exacerbation. The advantage of short-course prednisone is that it provides rapid and potent anti-inflammatory effects while minimizing the risks associated with long-term corticosteroid use.
In COPD, systemic corticosteroids including prednisone are used for acute exacerbations, with a typical regimen of 30 mg to 40 mg daily for 5 to 7 days. Longer courses do not provide additional benefit and increase the risk of adverse effects. The use of maintenance oral corticosteroids in COPD is strongly discouraged due to the unfavorable risk-benefit ratio, and inhaled corticosteroids are preferred for patients who require long-term anti-inflammatory therapy.
Sarcoidosis, a multisystem granulomatous disease of unknown etiology, frequently requires prednisone therapy for symptomatic pulmonary disease. The initial dose is typically 0.5 mg to 1 mg per kilogram daily, tapered to the lowest effective maintenance dose over 6 to 12 months. Many patients require long-term therapy, and the goal is to use the lowest dose that controls disease activity while minimizing side effects. Steroid-sparing agents such as methotrexate are often used to reduce prednisone requirements in patients with chronic sarcoidosis.
Interstitial lung diseases, including idiopathic pulmonary fibrosis and connective tissue disease-associated interstitial lung disease, may be treated with prednisone, though the evidence for efficacy varies by specific condition. In hypersensitivity pneumonitis, prednisone is effective for acute exacerbations and may help slow disease progression in some patients with chronic disease.
Clinical applications in rheumatology
Prednisone is a foundation of therapy for many rheumatologic conditions, providing rapid symptom relief while slower-acting disease-modifying antirheumatic drugs take effect. In rheumatoid arthritis, low-dose prednisone (less than 7.5 mg daily) is used as bridge therapy when initiating DMARDs, providing symptomatic relief within days while DMARDs take weeks to months to achieve full effect. Some patients with difficult-to-control rheumatoid arthritis require long-term low-dose prednisone, though efforts should be made to minimize cumulative exposure.
Polymyalgia rheumatica and giant cell arteritis are two conditions for which prednisone remains the clear standard of care. Polymyalgia rheumatica typically responds to 10 mg to 20 mg of prednisone daily, with dramatic improvement in pain and stiffness within days. Giant cell arteritis requires higher initial doses, typically 40 mg to 60 mg daily, to prevent vision loss and other ischemic complications. Both conditions may require treatment for one to two years or longer, with tapering guided by clinical symptoms and inflammatory markers.
Systemic lupus erythematosus requires prednisone for disease flares and for serious organ involvement. High-dose prednisone or intravenous methylprednisolone pulse therapy is used for severe lupus manifestations including lupus nephritis, cerebritis, and severe hemolytic anemia. The goal is to achieve disease control rapidly and then taper to the lowest effective dose, using steroid-sparing immunosuppressants to minimize cumulative corticosteroid exposure.
Vasculitides, including ANCA-associated vasculitis (granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis), are treated with high-dose prednisone in combination with cyclophosphamide or rituximab for induction of remission. Prednisone is typically initiated at 1 mg per kilogram daily and tapered over 6 to 12 months as remission is maintained with immunosuppressive therapy.
Clinical applications in hematology
In addition to its role in ITP and autoimmune hemolytic anemia, prednisone is used in various other hematologic conditions. In acquired hemophilia A, an autoimmune disorder characterized by inhibitors to factor VIII, prednisone is first-line therapy either alone or in combination with cyclophosphamide. The response rate is approximately 60% to 70%, with most responders achieving complete eradication of the inhibitor.
Prednisone is an essential component of many chemotherapy regimens for hematologic malignancies. In Hodgkin lymphoma and non-Hodgkin lymphoma, prednisone is included in standard regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine with or without prednisone). The corticosteroid contributes to the anti-lymphoma effect and also provides supportive benefits including antiemetic effects and reduction of infusion-related reactions.
In multiple myeloma, prednisone is used in combination with melphalan for elderly patients who are not candidates for stem cell transplantation, though lenalidomide-based regimens have largely replaced this approach. Prednisone also plays a role for complications of hematologic malignancies, including hypercalcemia of malignancy and spinal cord compression.
Clinical applications in gastroenterology
Prednisone is highly effective for inducing remission in moderate to severe ulcerative colitis and Crohn’s disease. In ulcerative colitis, prednisone 40 mg to 60 mg daily induces clinical remission in 60% to 80% of patients within 2 to 4 weeks. The dose is then tapered gradually over 8 to 12 weeks while initiating mesalamine, immunomodulators, or biologic agents for maintenance of remission.
In Crohn’s disease, prednisone is similarly effective for induction therapy, particularly for patients with moderate to severe disease activity. However, the response rate in Crohn’s disease is somewhat lower than in ulcerative colitis, and many patients become steroid-dependent, requiring chronic low-dose therapy to maintain remission. Steroid-sparing strategies with immunomodulators and biologic therapies are particularly important in Crohn’s disease to minimize cumulative prednisone exposure.
Autoimmune hepatitis responds well to prednisone therapy, typically in combination with azathioprine. The initial dose of prednisone is 30 mg to 60 mg daily, tapered to a maintenance dose of 5 mg to 10 mg daily as liver enzymes normalize. Most patients require long-term maintenance therapy to prevent relapse, though some patients may eventually be able to discontinue therapy after sustained remission.
Clinical applications in neurology
In multiple sclerosis, high-dose intravenous methylprednisolone (500 mg to 1000 mg daily for 3 to 5 days) is the standard therapy for acute relapses, though high-dose oral prednisone may be an effective alternative. The rapid anti-inflammatory effects accelerate recovery from neurologic deficits, though corticosteroids do not affect the long-term disease course or prevent future relapses.
Myasthenia gravis, an autoimmune disorder affecting the neuromuscular junction, is treated with prednisone in combination with acetylcholinesterase inhibitors and other immunosuppressants. Prednisone is initiated at low doses and gradually increased to minimize the risk of early exacerbation, which can occur in approximately 30% of patients during the first weeks of high-dose therapy.
Duchenne muscular dystrophy is one of the few conditions for which prednisone has demonstrated disease-modifying effects in a neurodegenerative disorder. Treatment with prednisone 0.75 mg per kilogram daily has been shown to prolong ambulation, improve pulmonary function, and slow the decline in muscle strength in boys with Duchenne muscular dystrophy. The benefit must be weighed against the significant side effects of long-term corticosteroid therapy in growing children.
Special populations
Pregnancy: Prednisone is classified as Pregnancy Category C. While animal studies have shown an increased risk of cleft palate and growth retardation with high doses, prednisone is often necessary for the management of maternal conditions such as asthma, lupus, and inflammatory bowel disease during pregnancy. The lowest effective dose should be used.
Breastfeeding: Prednisone and prednisolone are excreted in breast milk at low concentrations. The American Academy of Pediatrics considers prednisone compatible with breastfeeding, though caution is advised with high maternal doses. Delaying breastfeeding until four hours after the dose can minimize infant exposure.
Patient education and monitoring
Patients prescribed Deltasone should receive thorough education about their medication, including the importance of adhering to the prescribed dosing schedule, not abruptly discontinuing therapy, and recognizing signs of adrenal insufficiency including weakness, fatigue, nausea, vomiting, and low blood pressure. They should carry medical identification indicating their corticosteroid use.
Regular monitoring should include periodic assessment of blood pressure, blood glucose, serum electrolytes, bone mineral density, and ophthalmologic examination. Patients should maintain adequate calcium and vitamin D intake, engage in weight-bearing exercise, and avoid smoking and excessive alcohol to minimize the risk of osteoporosis.